Global Life Science Business Partnering (GLSBP) - January 2022

Highlights of January 2022

  1. Lupin Pharmaceuticals and Exeltis USA announced a promotional agreement for Exeltis to promote SOLOSEC along with Exeltis’ existing line of Women’s Health products, further enhancing value to OBGYNs and their patients.
  2. Care24, a leading home healthcare platform operating in Mumbai and Delhi, has been acquired by Human Life Management (HLM), a leading Japanese home medical support corporation.
  3. Glenmark Specialty has entered into an exclusive licensing agreement with Lotus International for commercializing its innovative nasal spray Ryaltris in Singapore, Hong Kong, and Vietnam.
  4. Lupin signs first partnership agreement with Foncoo for China.
  5. GC Cell Inks First Licensing Agreement for Immuncell-LC® With Rivaara Immune Private Limited in India.
  6. Arch Pharmalabs, Mumbai announced the signing of a Technology Access & Services Agreement with Orochem Technologies, USA, on an exclusive basis.
  7. Medtronic makes US$925 Million offer for Affera, aiming to break into advanced cardiac mapping market.
  8. Takeda to acquire Adaptate Biotherapeutics.
  9. Century Therapeutics inks deal with BMS on iPSC-derived allogeneic cell therapies.
  10. AstraZeneca has signed a collaboration agreement with Scorpion Therapeutics to discover, develop and commercialize precision medicines against previously hard-to-target cancer proteins, with the potential to transform oncology treatment.
  11. SCG Cell Therapy acquires technology from A*STAR for novel cancer treatment.
  12. Aurealis Therapeutics and Xbiome ink license deal for Greater China.

Highlights at Aagami:

  1. A fruitful BIOTECH SHOWCASE 2022 for Aagami with 30+ strategic meetings resulting in bright prospects for Aagami and its clients.
  2. Aagami received contract extensions from two clients.
  3. Aagami team wishes you a safe, healthy, successful, bright, prosperous and peaceful New Year 2022 and beyond.

INFOCUS: Select opportunities available at Aagami:

For Acquisition:

  1. Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package, & IP - for Next-generation biologics and substantial returns.

For Partnering/Licensing/ Investment:

  1. US FDA approved portable MRI Guided Treatment, Diagnosis and Screening ($40 Million Series C Open). For Urology applications.
  2. Seeking $7M Bridge to Series B (Over $5M fully committed) - Novel Evolution of Portable MRI and Robotics for Strokes and TBI. Total of $7.8M has been Raised so far.
  3. Series A - $25M Financing: Midwest US based Pharma’s First-in-Class Non-Opioid Analgesic for both chronic and acute Pain Relief – Seeking funding and licensing partnerships.
  4. Licensing, Co-development - Oncology assets such as Docetaxel, Cabazitaxel and Bendamustine, with low cost and accelerated route to market approval (From US subsidiary of a China HQ’d company). Negligible competition(2) for Bendamustine in the $600M US market.
  5. Seeking Investment/Strategic partnerships our Euronext listed French client’s Phase 2 injectable drug candidate (NFL-101) for smoking cessation. Dosing regimen: delivered subcutaneously, twice, one week apart.
  6. Available for licensing: Phase I asset for Moderate-Severe Pain; Fast Track designation; Clinical Study on-going.
  7. Available for licensing: Transdermal smart patch asset with Proprietary technology for Alzheimer’s Disease; IND filing in progress. Safer and non-irritable.
  8. Technology Licensing: Easy to apply Microneedle Array Patch (MAP) system for drugs, vaccines; better immune response than injection.
  9. Seeking $2.5M in Seed round – Natural and Soluble Melanin (100sX lower cost) with applications in Drugs, Biomedical, cosmetics, Aerospace, energy systems to name a few. Raised $650,000 till date from Indiebio Accelerator, SOSV and other VC funds. 40% commitment already received from existing investors.
×
Twitter